Statin-associated exacerbation of myasthenia gravis

Neurology

Volumn 63, Issue 11, 2004, Pages 2188-

  Cartwright, Michael S ^a,b   Jeffery, Douglas R ^a   Nuss, Geoffrey R ^b   Donofrio, Peter D ^a  

^a Department of Neurology ^*  (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MEVINOLIN; PRAVASTATIN; PYRIDOSTIGMINE; SIMVASTATIN; STATIN; UBIDECARENONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DYSARTHRIA; HUMAN; MALE; MYASTHENIA GRAVIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 10444257389     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000145708.03876.C3     Document Type: Article

References (6)

1. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112.
2. Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002;360:717.
3. Engel WK. Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? Lancet 2003;361:85-86.
4. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
5. Milani M, Ostlie N, Wang W, Conti-Fine BM. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann NY Acad Sci 2003;998:284-307.
6. Hargreaves IP, Heales S. Statins and myopathy. Lancet 2002;359:711-712.